Cyrus Harmon - 09 Dec 2024 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Role
Director
Signature
/s/ Shane Kovacs, Attorney-in-Fact
Issuer symbol
OLMA
Transactions as of
09 Dec 2024
Transactions value $
-$147,956
Form type
4
Filing time
11 Dec 2024, 19:56:44 UTC
Previous filing
31 Jul 2024
Next filing
13 Jun 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OLMA Common Stock Award $0 +29,250 +3.89% $0 780,533 09 Dec 2024 Direct F1
transaction OLMA Common Stock Sale -$77,358 -8,256 -1.06% $9.37 772,277 10 Dec 2024 Direct F2, F3
transaction OLMA Common Stock Sale -$68,916 -7,958 -1.03% $8.66 764,319 11 Dec 2024 Direct F2, F4
transaction OLMA Common Stock Sale -$1,680 -179 -0.02% $9.39 764,140 11 Dec 2024 Direct F2, F5
holding OLMA Common Stock 122,028 09 Dec 2024 See Footnote F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On November 11, 2022, the Reporting Person was granted certain performance restricted stock units ("PRSUs") for 45,000 shares, which were subject to vesting upon certification by the Compensation Committee of the Company's achievement of two different performance milestones. 35% of the award previously vested on November 20, 2023. On December 9, 2024, the Compensation Committee certified that the remaining 65% of the award vested based on achievement of certain performance criteria.
F2 The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
F3 The weighted average sale price for the transaction reported was $9.37, and the range of prices was between $8.89 and $9.70. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F4 The weighted average sale price for the transaction reported was $8.66, and the range of prices was between $8.22 and $9.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F5 The weighted average sale price for the transaction reported was $9.39, and the range of prices was between $9.31 and $9.74. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F6 The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager.